| 1 | Circulating tumor DNA for predicting recurrence in patients with operable breast cancer: a systematic review and meta-analysis | 5.5 | 44 | Citations (PDF) |
| 2 | Long-term Multimodal Recording Reveals Epigenetic Adaptation Routes in Dormant Breast Cancer Cells | 25.6 | 34 | Citations (PDF) |
| 3 | A Functional Survey of the Regulatory Landscape of Estrogen Receptor–Positive Breast Cancer Evolution | 25.6 | 4 | Citations (PDF) |
| 4 | Immune and gene-expression profiling in estrogen receptor low and negative early breast cancer | 4.7 | 24 | Citations (PDF) |
| 5 | Induction of the TEAD Coactivator VGLL1 by Estrogen Receptor–Targeted Therapy Drives Resistance in Breast Cancer | 0.6 | 7 | Citations (PDF) |
| 6 | Use of PEAK PlasmaBlade in implant-based breast reconstruction and radiotherapy: new strategy to reduce complications | 1.5 | 5 | Citations (PDF) |
| 7 | ESR1 gene amplification and MAP3K mutations are selected during adjuvant endocrine therapies in relapsing Hormone Receptor-positive, HER2-negative breast cancer (HR+ HER2- BC) | 3.3 | 16 | Citations (PDF) |
| 8 | Fatty acid synthase as a new therapeutic target for HER2-positive gastric cancer | 4.2 | 18 | Citations (PDF) |
| 9 | Prognostic significance of HER2-low status in HR-positive/HER2-negative advanced breast cancer treated with CDK4/6 inhibitors | 6.5 | 21 | Citations (PDF) |
| 10 | Pan-TRK immunohistochemistry as screening tool for NTRK fusions: A diagnostic workflow for the identification of positive patients in clinical practice | 1.6 | 6 | Citations (PDF) |
| 11 | Fasting-Mimicking Diet Is Safe and Reshapes Metabolism and Antitumor Immunity in Patients with Cancer | 25.6 | 275 | Citations (PDF) |
| 12 | Copy number alterations analysis of primary tumor tissue and circulating tumor cells from patients with early-stage triple negative breast cancer | 3.5 | 16 | Citations (PDF) |
| 13 | Tumor infiltrating lymphocyte stratification of prognostic staging of early-stage triple negative breast cancer | 6.5 | 68 | Citations (PDF) |
| 14 | Mammographic density to predict response to neoadjuvant systemic breast cancer therapy | 2.4 | 9 | Citations (PDF) |
| 15 | Acquired Resistance Mechanisms to PD-L1 Blockade in a Patient With Microsatellite Instability-High Extrahepatic Cholangiocarcinoma | 2.1 | 3 | Citations (PDF) |
| 16 | Management of BRCA Tumour Testing in an Integrated Molecular Tumour Board Multidisciplinary Model | 2.7 | 4 | Citations (PDF) |
| 17 | Genetic Layout of Melanoma Lesions Is Associated with BRAF/MEK-Targeted Therapy Resistance and Transcriptional Profiles | 2.3 | 12 | Citations (PDF) |
| 18 | A three-gene signature based on <i>MYC</i>, <i>BCL-2</i> and <i>NFKBIA</i> improves risk stratification in diffuse large B-cell lymphoma | 4.1 | 11 | Citations (PDF) |
| 19 | <scp>STAT3</scp> activation in <scp>HER2</scp>‐positive breast cancers: Analysis of data from a large prospective trial | 4.5 | 10 | Citations (PDF) |
| 20 | The use of genomic tests in patients with breast cancer in Lombardy: a successful healthcare model | 1.5 | 5 | Citations (PDF) |
| 21 | Transplantation of autologous extracellular vesicles for cancer-specific targeting | 11.5 | 48 | Citations (PDF) |
| 22 | Detection of Genomically Aberrant Cells within Circulating Tumor Microemboli (CTMs) Isolated from Early-Stage Breast Cancer Patients | 4.0 | 10 | Citations (PDF) |
| 23 | Next-Generation Sequencing in Clinical Practice: Is It a Cost-Saving Alternative to a Single-Gene Testing Approach? | 1.7 | 63 | Citations (PDF) |
| 24 | Impact of Baseline and On-Treatment Glycemia on Everolimus-Exemestane Efficacy in Patients with Hormone Receptor–Positive Advanced Breast Cancer (EVERMET) | 6.9 | 9 | Citations (PDF) |
| 25 | Automated classification of cancer morphology from Italian pathology reports using Natural Language Processing techniques: A rule-based approach | 3.8 | 36 | Citations (PDF) |
| 26 | Blood-based genomics of triple-negative breast cancer progression in patients treated with neoadjuvant chemotherapy | 5.5 | 56 | Citations (PDF) |
| 27 | Multigene tests for breast cancer: the physician’s perspective | 1.7 | 16 | Citations (PDF) |
| 28 | T Cells Expressing Receptor Recombination/Revision Machinery Are Detected in the Tumor Microenvironment and Expanded in Genomically Over-unstable Models | 4.2 | 8 | Citations (PDF) |
| 29 | Circulating Tumor Cell Clusters Are Frequently Detected in Women with Early-Stage Breast Cancer | 4.0 | 46 | Citations (PDF) |
| 30 | COVID-19 Pandemic: Huge Stress Test for Health System Could Be a Great Opportunity to Update the Workflow in a Modern Surgical Pathology | 4.0 | 6 | Citations (PDF) |
| 31 | Targeting lipid metabolism is an emerging strategy to enhance the efficacy of anti-HER2 therapies in HER2-positive breast cancer | 8.8 | 38 | Citations (PDF) |
| 32 | Spatial epi-proteomics enabled by histone post-translational modification analysis from low-abundance clinical samples | 4.0 | 42 | Citations (PDF) |
| 33 | Multi-Gene Testing Overview with a Clinical Perspective in Metastatic Triple-Negative Breast Cancer | 4.5 | 14 | Citations (PDF) |
| 34 | Real-World Data on NGS Diagnostics: a survey from the Italian Society of Pathology (SIAPeC) NGS Network | 2.2 | 15 | Citations (PDF) |
| 35 | Integrated Molecular and Immune Phenotype of HER2-Positive Breast Cancer and Response to Neoadjuvant Therapy: A NeoALTTO Exploratory Analysis | 6.9 | 13 | Citations (PDF) |
| 36 | <i>CDKN2A</i> deletion is a frequent event associated with poor outcome in patients with peripheral T-cell lymphoma not otherwise specified (PTCL-NOS) | 4.1 | 37 | Citations (PDF) |
| 37 | The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group | 6.5 | 214 | Citations (PDF) |
| 38 | Hormone receptor status influences the impact of body mass index and hyperglycemia on the risk of tumor relapse in early-stage HER2-positive breast cancer patients | 3.8 | 7 | Citations (PDF) |
| 39 | L’oncologia mutazionale del carcinoma polmonare: marcatori molecolari, farmaci, condizioni negoziali ed esperienze in centri di riferimento nazionale | 0.0 | 1 | Citations (PDF) |
| 40 | Cancer Associated Fibroblasts and Senescent Thyroid Cells in the Invasive Front of Thyroid Carcinoma | 4.0 | 48 | Citations (PDF) |
| 41 | Anticancer innovative therapy: Highlights from the ninth annual meeting | 10.8 | 0 | Citations (PDF) |
| 42 | Myeloma Cells Deplete Bone Marrow Glutamine and Inhibit Osteoblast Differentiation Limiting Asparagine Availability | 4.0 | 33 | Citations (PDF) |
| 43 | Phylogenetic reconstruction of breast cancer reveals two routes of metastatic dissemination associated with distinct clinical outcome | 9.9 | 36 | Citations (PDF) |
| 44 | A cell-of-origin epigenetic tracer reveals clinically distinct subtypes of high-grade serous ovarian cancer | 9.7 | 20 | Citations (PDF) |
| 45 | Characterization of Stromal Tumor-infiltrating Lymphocytes and Genomic Alterations in Metastatic Lobular Breast Cancer | 6.9 | 33 | Citations (PDF) |
| 46 | A new case of myelodysplastic syndrome associated with t(3;3)(q21;q26) and inv(11)(p15q22) | 1.5 | 1 | Citations (PDF) |
| 47 | Clinical performance of contrast-enhanced spectral mammography in pre-surgical evaluation of breast malignant lesions in dense breasts: a single center study | 2.4 | 29 | Citations (PDF) |
| 48 | Hormone Receptor Loss in Breast Cancer: Molecular Mechanisms, Clinical Settings, and Therapeutic Implications | 4.8 | 61 | Citations (PDF) |
| 49 | Response of a comprehensive cancer center to the COVID-19 pandemic: the experience of the Fondazione IRCCS–Istituto Nazionale dei Tumori di Milano | 1.5 | 33 | Citations (PDF) |
| 50 | Application of a risk-management framework for integration of stromal tumor-infiltrating lymphocytes in clinical trials | 6.5 | 19 | Citations (PDF) |
| 51 | Report on computational assessment of Tumor Infiltrating Lymphocytes from the International Immuno-Oncology Biomarker Working Group | 6.5 | 138 | Citations (PDF) |
| 52 | Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer | 6.5 | 165 | Citations (PDF) |
| 53 | Oral Capecitabine-Vinorelbine Is Associated with Longer Overall Survival When Compared to Single-Agent Capecitabine in Patients with Hormone Receptor-Positive Advanced Breast Cancer | 4.0 | 7 | Citations (PDF) |
| 54 | The path to a better biomarker: application of a risk management framework for the implementation of PD‐L1 and TILs as immuno‐oncology biomarkers in breast cancer clinical trials and daily practice | 5.0 | 190 | Citations (PDF) |
| 55 | Improved Prognostic Prediction in Never-Smoker Lung Cancer Patients by Integration of a Systemic Inflammation Marker with Tumor Immune Contexture Analysis | 4.0 | 1 | Citations (PDF) |
| 56 | Prognostic and predictive value of cell cycle progression (CCP) score in ductal carcinoma in situ of the breast | 4.9 | 4 | Citations (PDF) |
| 57 | OC-042 Genomic characterization of oral premalignant lesions to identify high-risk molecular clusters | 2.0 | 0 | Citations (PDF) |
| 58 | MGMT methylation in metastatic pancreatic cancer (mPAC): A single center experience | 10.2 | 0 | Citations (PDF) |
| 59 | Is MGMT methylation a new therapeutic target for biliary tract cancer? | 10.2 | 1 | Citations (PDF) |
| 60 | Tumour-infiltrating lymphocytes (TILs) in patients with epithelial ovarian cancer undergoing neoadjuvant chemotherapy: A retrospective study | 10.2 | 2 | Citations (PDF) |
| 61 | Accuracy of pathologic evaluation for thymic epithelial tumors in an Italian reference centre | 10.2 | 0 | Citations (PDF) |
| 62 | Prognostic role of CD73 in metastatic non small cell lung cancer according to the presence of driver alterations | 10.2 | 0 | Citations (PDF) |
| 63 | Single-cell transcriptomics reveals multi-step adaptations to endocrine therapy | 13.9 | 113 | Citations (PDF) |
| 64 | Development of Personalized Therapeutic Strategies by Targeting Actionable Vulnerabilities in Metastatic and Chemotherapy-Resistant Breast Cancer PDXs | 4.8 | 18 | Citations (PDF) |
| 65 | Microenvironment and tumor inflammatory features improve prognostic prediction in gastro‐entero‐pancreatic neuroendocrine neoplasms | 3.4 | 38 | Citations (PDF) |
| 66 | Optimizing checkpoint inhibitors therapy for relapsed or progressive classic Hodgkin lymphoma by multiplex immunohistochemistry of the tumor microenvironment | 2.7 | 10 | Citations (PDF) |
| 67 | SREBP1 drives Keratin-80-dependent cytoskeletal changes and invasive behavior in endocrine-resistant ERα breast cancer | 13.9 | 63 | Citations (PDF) |
| 68 | Identification of potentially druggable molecular alterations in skin adnexal malignancies | 1.4 | 14 | Citations (PDF) |
| 69 | Prognostic impact of ATM mutations in patients with metastatic colorectal cancer | 3.5 | 54 | Citations (PDF) |
| 70 | The landscape of d16HER2 splice variant expression across HER2-positive cancers | 3.5 | 28 | Citations (PDF) |
| 71 | Integration of transcriptional and mutational data simplifies the stratification of peripheral T‐cell lymphoma | 6.1 | 19 | Citations (PDF) |
| 72 | Inhibition of SIRT1 deacetylase and p53 activation uncouples the anti-inflammatory and chemopreventive actions of NSAIDs | 5.7 | 51 | Citations (PDF) |
| 73 | ESR1 mutations in metastatic lobular breast cancer patients | 6.5 | 32 | Citations (PDF) |
| 74 | WDR5 inhibition halts metastasis dissemination by repressing the mesenchymal phenotype of breast cancer cells | 4.9 | 37 | Citations (PDF) |
| 75 | Targeted-Gene Sequencing to Catch Triple Negative Breast Cancer Heterogeneity before and after Neoadjuvant Chemotherapy | 4.0 | 17 | Citations (PDF) |
| 76 | Antibody–Fc/FcR Interaction on Macrophages as a Mechanism for Hyperprogressive Disease in Non–small Cell Lung Cancer Subsequent to PD-1/PD-L1 Blockade | 6.9 | 375 | Citations (PDF) |
| 77 | Targeting the PI3K/AKT/mTOR pathway in biliary tract cancers: A review of current evidences and future perspectives | 9.8 | 117 | Citations (PDF) |
| 78 | Mitosis perturbation by MASTL depletion impairs the viability of thyroid tumor cells | 8.8 | 19 | Citations (PDF) |
| 79 | Exploiting FAsting-mimicking Diet and MEtformin to Improve the Efficacy of Platinum-pemetrexed Chemotherapy in Advanced LKB1-inactivated Lung Adenocarcinoma: The FAME Trial | 2.8 | 38 | Citations (PDF) |
| 80 | Ki-67 and presence of liver metastases identify different progression-risk classes in pancreatic neuroendocrine neoplasms (pNEN) undergoing resection | 0.9 | 17 | Citations (PDF) |
| 81 | Impact of systemic and tumor lipid metabolism on everolimus efficacy in advanced pancreatic neuroendocrine tumors (pNETs) | 4.5 | 26 | Citations (PDF) |
| 82 | Axillary nodal involvement by primary tumor features in early breast cancer: an analysis of 2600 patients | 2.2 | 2 | Citations (PDF) |
| 83 | Gastroblastoma in Adulthood—A Rarity among Rare Cancers—A Case Report and Review of the Literature | 0.3 | 12 | Citations (PDF) |
| 84 | Immune Infiltration in Invasive Lobular Breast Cancer | 4.7 | 106 | Citations (PDF) |
| 85 | Extensive and systematic rewiring of histone post-translational modifications in cancer model systems | 15.7 | 39 | Citations (PDF) |
| 86 | Tumor infiltrating lymphocytes in early breast cancer | 2.4 | 133 | Citations (PDF) |
| 87 | A gene signature to predict high tumor-infiltrating lymphocytes after neoadjuvant chemotherapy and outcome in patients with triple-negative breast cancer | 10.2 | 57 | Citations (PDF) |
| 88 | Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ: A report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer | 14.1 | 372 | Citations (PDF) |
| 89 | Biomarkers of Primary Resistance to Trastuzumab in HER2-Positive Metastatic Gastric Cancer Patients: the AMNESIA Case-Control Study | 6.9 | 100 | Citations (PDF) |
| 90 | Best practices for the management of thymic epithelial tumors: A position paper by the Italian collaborative group for ThYmic MalignanciEs (TYME) | 9.8 | 54 | Citations (PDF) |
| 91 | Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23-01): 10-year follow-up of a randomised, controlled phase 3 trial | 26.0 | 475 | Citations (PDF) |
| 92 | Enhancer mapping uncovers phenotypic heterogeneity and evolution in patients with luminal breast cancer | 39.5 | 116 | Citations (PDF) |
| 93 | RELEVENT Trial: Phase II Trial of Ramucirumab, Carboplatin, and Paclitaxel in Previously Untreated Thymic Carcinoma/B3 Thymoma With Area of Carcinoma | 2.8 | 21 | Citations (PDF) |
| 94 | RANBP9 affects cancer cells response to genotoxic stress and its overexpression is associated with worse response to platinum in NSCLC patients | 6.7 | 20 | Citations (PDF) |
| 95 | Scoring of tumor-infiltrating lymphocytes: From visual estimation to machine learning | 14.1 | 140 | Citations (PDF) |
| 96 | Breast cancer diagnosed during pregnancy is associated with enrichment of non-silent mutations, mismatch repair deficiency signature and mucin mutations | 6.5 | 29 | Citations (PDF) |
| 97 | Temozolomide and irinotecan (TEMIRI regimen) as salvage treatment of irinotecan-sensitive advanced colorectal cancer patients bearing MGMT methylation | 10.2 | 36 | Citations (PDF) |
| 98 | Adjuvant therapy in patients with ductal carcinoma in situ of the breast: The Pandora’s box | 9.8 | 24 | Citations (PDF) |
| 99 | A Presurgical Study of Lecithin Formulation of Green Tea Extract in Women with Early Breast Cancer | 1.5 | 71 | Citations (PDF) |
| 100 | Unfavorable prognostic role of tumor-infiltrating lymphocytes in hormone-receptor positive, HER2 negative metastatic breast cancer treated with metronomic chemotherapy | 2.4 | 25 | Citations (PDF) |
| 101 | Pre‐clinical validation of a selective anti‐cancer stem cell therapy for Numb‐deficient human breast cancers | 7.2 | 42 | Citations (PDF) |
| 102 | The prevalence and clinical relevance of tumor-infiltrating lymphocytes (TILs) in ductal carcinoma in situ of the breast | 10.2 | 89 | Citations (PDF) |
| 103 | ESO-ESMO 3rd international consensus guidelines for breast cancer in young women (BCY3) | 2.4 | 224 | Citations (PDF) |
| 104 | Mutations targeting the coagulation pathway are enriched in brain metastases | 3.5 | 10 | Citations (PDF) |
| 105 | Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non–Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors | 2.4 | 715 | Citations (PDF) |
| 106 | Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ, Metastatic Tumor Deposits and Areas for Further Research | 2.4 | 613 | Citations (PDF) |
| 107 | Prognostic value of tumour-infiltrating lymphocytes in small HER2-positive breast cancer | 5.1 | 8 | Citations (PDF) |
| 108 | Over-using chemotherapy in the adjuvant setting | 2.4 | 9 | Citations (PDF) |
| 109 | PAT-H-MS coupled with laser microdissection to study histone post-translational modifications in selected cell populations from pathology samples | 4.0 | 20 | Citations (PDF) |
| 110 | Phosphorylation of SOS1 on tyrosine 1196 promotes its RAC GEF activity and contributes to BCR-ABL leukemogenesis | 10.4 | 35 | Citations (PDF) |
| 111 | Metabolic shifts in residual breast cancer drive tumor recurrence | 10.7 | 155 | Citations (PDF) |
| 112 | A retrospective international study on primary extranodal marginal zone lymphoma of the lung (BALT lymphoma) on behalf of International Extranodal Lymphoma Study Group (IELSG) | 2.2 | 58 | Citations (PDF) |
| 113 | Tumor-infiltrating lymphocytes (TILs) are a powerful prognostic marker in patients with triple-negative breast cancer enrolled in the IBCSG phase III randomized clinical trial 22-00 | 2.4 | 107 | Citations (PDF) |
| 114 | Standardized evaluation of tumor-infiltrating lymphocytes in breast cancer: results of the ring studies of the international immuno-oncology biomarker working group | 4.9 | 278 | Citations (PDF) |
| 115 | Polycomb dysregulation in gliomagenesis targets a Zfp423-dependent differentiation network | 13.9 | 26 | Citations (PDF) |
| 116 | Benefit of low‐dose tamoxifen in a large observational cohort of high risk ER positive breast DCIS | 4.5 | 38 | Citations (PDF) |
| 117 | Genetic code expansion for multiprotein complex engineering | 25.9 | 72 | Citations (PDF) |
| 118 | Oral Chemotherapy and Patient Perspective in Solid Tumors: A National Survey by the Italian Association of Medical Oncology | 1.5 | 4 | Citations (PDF) |
| 119 | Biomarkers for the identification of recurrence in human epidermal growth factor receptor 2-positive breast cancer patients | 2.2 | 6 | Citations (PDF) |
| 120 | Serum HER2 Extracellular Domain Levels and Her2 Circulating Tumor Cell Status in Patients with Metastatic Breast Cancer | 2.4 | 7 | Citations (PDF) |
| 121 | A Randomized, Placebo-Controlled, Phase II, Presurgical Biomarker Trial of Celecoxib Versus Exemestane in Postmenopausal Breast Cancer Patients | 1.5 | 16 | Citations (PDF) |
| 122 | A Presurgical Study of Oral Silybin-Phosphatidylcholine in Patients with Early Breast Cancer | 1.5 | 46 | Citations (PDF) |
| 123 | Clinical validity of tumor-infiltrating lymphocytes analysis in patients with triple-negative breast cancer | 10.2 | 142 | Citations (PDF) |
| 124 | Pathology Tissue-quantitative Mass Spectrometry Analysis to Profile Histone Post-translational Modification Patterns in Patient Samples | 3.0 | 51 | Citations (PDF) |
| 125 | RNAi screens identify CHD4 as an essential gene in breast cancer growth | 1.7 | 43 | Citations (PDF) |
| 126 | Core needle biopsy as a front line diagnostic approach for lymphoma patients | 2.2 | 15 | Citations (PDF) |
| 127 | Molecular investigation of coexistent chronic myeloid leukaemia and peripheral T-cell lymphoma – a case report | 3.5 | 2 | Citations (PDF) |
| 128 | Redox-Mediated Suberoylanilide Hydroxamic Acid Sensitivity in Breast Cancer | 6.5 | 15 | Citations (PDF) |
| 129 | Risk of subsequentin situ and invasive breast cancer in human epidermal growth factor receptor 2-positive ductal carcinomain situ | 10.2 | 57 | Citations (PDF) |
| 130 | Tumour infiltrating lymphocytes (TILs) in breast cancer during pregnancy | 2.4 | 31 | Citations (PDF) |
| 131 | RANK-ligand (RANKL) expression in young breast cancer patients and during pregnancy | 4.9 | 166 | Citations (PDF) |
| 132 | Effect of Metformin on Breast Ductal Carcinoma <i>In Situ</i> Proliferation in a Randomized Presurgical Trial | 1.5 | 29 | Citations (PDF) |
| 133 | Outcome of Immediate Breast Reconstruction in Patients With Nonendocrine-Responsive Breast Cancer: A Monoinstitutional Case-Control Study | 2.4 | 14 | Citations (PDF) |
| 134 | Chlorambucil–rituximab as first‐line therapy in patients affected by follicular non‐Hodgkin's lymphoma: a retrospective single‐centre study | 2.2 | 12 | Citations (PDF) |
| 135 | DMXL2 drives epithelial to mesenchymal transition in hormonal therapy resistant breast cancer through notch hyper-activation | 1.7 | 37 | Citations (PDF) |
| 136 | Efficacy of<sup>90</sup>Yttrium-ibritumomab tiuxetan in relapsed/refractory extranodal marginal-zone lymphoma | 2.2 | 26 | Citations (PDF) |
| 137 | Prevalence of <i><scp>A</scp>chromobacter xylosoxidans</i> in pulmonary mucosa‐associated lymphoid tissue lymphoma in different regions of <scp>E</scp>urope | 2.4 | 63 | Citations (PDF) |
| 138 | Association of molecular subtypes with Ki-67 changes in untreated breast cancer patients undergoing pre-surgical trials | 10.2 | 30 | Citations (PDF) |
| 139 | Proposed new clinicopathological surrogate definitions of luminal A and luminal B (HER2-negative) intrinsic breast cancer subtypes | 4.9 | 159 | Citations (PDF) |
| 140 | Differential effects of metformin on breast cancer proliferation according to markers of insulin resistance and tumor subtype in a randomized presurgical trial | 2.4 | 71 | Citations (PDF) |
| 141 | Prevalence and Clinicopathologic Correlates of O6-Methylguanine-DNA Methyltransferase Methylation Status in Patients With Triple-Negative Breast Cancer Treated Preoperatively by Alkylating Drugs | 2.4 | 11 | Citations (PDF) |
| 142 | Functional characterization of a novel FGFR1OP‐RET rearrangement in hematopoietic malignancies | 4.2 | 29 | Citations (PDF) |
| 143 | Reply to letter by Ieni et al. | 5.1 | 0 | Citations (PDF) |
| 144 | Outcome of Male Breast Cancer: A Matched Single-Institution Series | 2.4 | 38 | Citations (PDF) |
| 145 | Survival Outcomes in Breast Cancer Patients With Low Estrogen/Progesterone Receptor Expression | 2.4 | 60 | Citations (PDF) |
| 146 | A meta-analysis of oestrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 discordance between primary breast cancer and metastases | 5.1 | 249 | Citations (PDF) |
| 147 | Biology of breast cancer during pregnancy using genomic profiling | 3.9 | 65 | Citations (PDF) |
| 148 | Prognostic relevance of peritumoral vascular invasion in immunohistochemically defined subtypes of node-positive breast cancer | 2.4 | 11 | Citations (PDF) |
| 149 | 7q11.23 dosage-dependent dysregulation in human pluripotent stem cells affects transcriptional programs in disease-relevant lineages | 26.1 | 122 | Citations (PDF) |
| 150 | Estramustine phosphate sodium in heavily pretreated patients with metastatic breast cancer: a retrospective consecutive case series | 2.4 | 2 | Citations (PDF) |
| 151 | Immediate breast reconstruction with expander in pregnant breast cancer patients | 2.4 | 57 | Citations (PDF) |
| 152 | The clinical relevance of micropapillary carcinoma of the breast: a case–control study | 3.7 | 59 | Citations (PDF) |
| 153 | A randomized phase II presurgical trial of weekly low-dose tamoxifen versus raloxifene versus placebo in premenopausal women with estrogen receptor-positive breast cancer | 4.9 | 25 | Citations (PDF) |
| 154 | Progesterone receptor loss identifies Luminal B breast cancer subgroups at higher risk of relapse | 10.2 | 101 | Citations (PDF) |
| 155 | Additional prognostic value of the 70-gene signature (MammaPrint®) among breast cancer patients with 4–9 positive lymph nodes | 2.4 | 48 | Citations (PDF) |
| 156 | Pathological features and survival outcomes of very young patients with early breast cancer: How much is “very young”? | 2.4 | 34 | Citations (PDF) |
| 157 | Heterogeneity of Triple-Negative Breast Cancer: Histologic Subtyping to Inform the Outcome | 2.4 | 145 | Citations (PDF) |
| 158 | Immunohistochemically Defined Subtypes and Outcome of Apocrine Breast Cancer | 2.4 | 59 | Citations (PDF) |
| 159 | The effect of metformin on apoptosis in a breast cancer presurgical trial | 5.7 | 75 | Citations (PDF) |
| 160 | Cell Reprogramming Requires Silencing of a Core Subset of Polycomb Targets | 3.3 | 63 | Citations (PDF) |
| 161 | Effect of low-dose tamoxifen after surgical excision of ductal intraepithelial neoplasia: results of a large retrospective monoinstitutional cohort study | 10.2 | 19 | Citations (PDF) |
| 162 | Complementary Populations of Human Adipose CD34+ Progenitor Cells Promote Growth, Angiogenesis, and Metastasis of Breast Cancer | 0.6 | 99 | Citations (PDF) |
| 163 | NPMc+ and FLT3_ITD mutations cooperate in inducing acute leukaemia in a novel mouse model | 10.4 | 45 | Citations (PDF) |
| 164 | Tailoring treatment for ductal intraepithelial neoplasia of the breast according to Ki-67 and molecular phenotype | 5.7 | 40 | Citations (PDF) |
| 165 | Discordant hormone receptor and human epidermal growth factor receptor 2 status in bone metastases compared to primary breast cancer | 1.8 | 63 | Citations (PDF) |
| 166 | Outcome and clinical–biological characteristics of patients with advanced breast cancer undergoing removal of ovarian/pelvic metastases | 10.2 | 2 | Citations (PDF) |
| 167 | The biological features and prognosis of breast cancer diagnosed during pregnancy: A case-control study | 1.8 | 70 | Citations (PDF) |
| 168 | Estrogen Receptor in Breast Ductal Carcinoma in Situ: Good Cop, Bad Cop? | 21.6 | 5 | Citations (PDF) |
| 169 | Spontaneous Cell Fusion of Acute Leukemia Cells and Macrophages Observed in Cells with Leukemic Potential | 7.2 | 24 | Citations (PDF) |
| 170 | Outcome of special types of luminal breast cancer | 10.2 | 107 | Citations (PDF) |
| 171 | The White Adipose Tissue Used in Lipotransfer Procedures Is a Rich Reservoir of CD34+ Progenitors Able to Promote Cancer Progression | 0.6 | 142 | Citations (PDF) |
| 172 | Methylation of O 6-methylguanine-DNA methyltransferase (MGMT) promoter gene in triple-negative breast cancer patients | 2.4 | 39 | Citations (PDF) |
| 173 | Prognostic significance of Ki-67 labeling index after short-term presurgical tamoxifen in women with ER-positive breast cancer | 10.2 | 79 | Citations (PDF) |
| 174 | Rituximab in Hodgkin lymphoma: Is the target always a hit? | 9.8 | 41 | Citations (PDF) |
| 175 | Should liver metastases of breast cancer be biopsied to improve treatment choice? | 10.2 | 108 | Citations (PDF) |
| 176 | The lymphoma-associated NPM-ALK oncogene elicits a p16INK4a/pRb-dependent tumor-suppressive pathwayBlood, 2011, 117, 6617-6626 | 4.2 | 24 | Citations (PDF) |
| 177 | Prognosis in women with small (T1mic,T1a,T1b) node-negative operable breast cancer by immunohistochemically selected subtypes | 2.4 | 101 | Citations (PDF) |
| 178 | In vitro efficacy of tyrosine kinase inhibitors: SYK and BCR-ABL inhibitors in lymphomas | 2.2 | 3 | Citations (PDF) |
| 179 | Lapatinib Activity in Premalignant Lesions and HER-2–Positive Cancer of the Breast in a Randomized, Placebo-Controlled Presurgical Trial | 1.5 | 55 | Citations (PDF) |
| 180 | Tissue Microarrays in Diffuse Large B-Cell Lymphomas | 1.0 | 1 | Citations (PDF) |
| 181 | Metaplastic carcinoma with extensive dendritic cell differentiation: a previously unrecognised type of triple-negative breast cancer | 10.2 | 2 | Citations (PDF) |
| 182 | CD45-CD34+ Endothelial Progenitor Cells (EPCs) from Human Adipose Tissue Promote Tumor Growth and MetastasesBlood, 2011, 118, 2208-2208 | 4.2 | 0 | Citations (PDF) |
| 183 | Efficacy of 90yttrium-Ibritumomab Tiuxetan in Extranodal Marginal-Zone Lymphoma,Blood, 2011, 118, 3713-3713 | 4.2 | 0 | Citations (PDF) |
| 184 | Potential Pathogenetic Role of Achromobacter (Alcaligenes) Xylosoxidans in Primary Extranodal Marginal Zone Lymphoma of the Lung (BALT-Lymphoma): Update of the Results of a Retrospective Analysis on Behalf of IELSGBlood, 2011, 118, 880-880 | 4.2 | 2 | Citations (PDF) |
| 185 | A monoclonal antibody against mutated nucleophosmin 1 for the molecular diagnosis of acute myeloid leukemiasBlood, 2010, 116, 2096-2102 | 4.2 | 38 | Citations (PDF) |
| 186 | Pathological complete response after preoperative systemic therapy and outcome: relevance of clinical and biologic baseline features | 2.4 | 66 | Citations (PDF) |
| 187 | If it is in the marrow, is it also in the blood? An analysis of 1,000 paired samples from patients with B-cell non-Hodgkin lymphoma | 3.1 | 20 | Citations (PDF) |
| 188 | Genomic lesions associated with a different clinical outcome in diffuse large B‐Cell lymphoma treated with R‐CHOP‐21 | 2.4 | 47 | Citations (PDF) |
| 189 | Prognosis and adjuvant treatment effects in selected breast cancer subtypes of very young women (<35 years) with operable breast cancer | 10.2 | 224 | Citations (PDF) |
| 190 | Is there a role for 'modified VAD' in the treatment of multiple myeloma? | 0.9 | 0 | Citations (PDF) |
| 191 | Bona Fide Primary Merkel Cell Carcinoma of an Intraparotid Lymph Node in a HIV-Positive Patient | 1.0 | 8 | Citations (PDF) |
| 192 | Rituximab and subcutaneous cladribine in chronic lymphocytic leukemia for newly diagnosed and relapsed patients | 1.5 | 11 | Citations (PDF) |
| 193 | PRIMARY EXTRANODAL MARGINAL ZONE LYMPHOMA of the LUNG (BALT-LYMPHOMA): Results of a Retrospective Analysis on Behalf of IELSGBlood, 2010, 116, 1770-1770 | 4.2 | 0 | Citations (PDF) |
| 194 | Rituximab Plus Chlorambucil Compared with Chlorambucil and Prednisone In Patients with Untreated Follicular LymphomaBlood, 2010, 116, 3956-3956 | 4.2 | 0 | Citations (PDF) |
| 195 | Management of Anaplastic Large-Cell Lymphoma During Pregnancy | 21.6 | 8 | Citations (PDF) |
| 196 | Primary follicular and marginal-zone lymphoma of the breast: clinical features, prognostic factors and outcome: a study by the International Extranodal Lymphoma Study Group | 10.2 | 101 | Citations (PDF) |
| 197 | A risk score to predict disease-free survival in patients not achieving a pathological complete remission after preoperative chemotherapy for breast cancer | 10.2 | 37 | Citations (PDF) |
| 198 | 0071 The 70-gene MammaPrint profile allows to identify a subgroup of very good-prognostic patients with primary breast cancer and 4-9 positive lymph nodes | 2.4 | 1 | Citations (PDF) |
| 199 | Minimal axillary lymph node involvement in breast cancer has different prognostic implications according to the staging procedure | 2.4 | 31 | Citations (PDF) |
| 200 | Magnetic resonance imaging of primary breast lymphoma | 4.1 | 17 | Citations (PDF) |
| 201 | Daily clinical practice of fresh tumour tissue freezing and gene expression profiling; logistics pilot study preceding the MINDACT trial | 5.1 | 36 | Citations (PDF) |
| 202 | BCL2, BCL6, MYC, MALT 1, and BCL10 rearrangements in nodal diffuse large B-cell lymphomas: a multicenter evaluation of a new set of fluorescent in situ hybridization probes and correlation with clinical outcome | 2.4 | 104 | Citations (PDF) |
| 203 | Confocal laser endomicroscopy diagnosis of gastric adenocarcinoma in a patient treated for gastric diffuse large-B-cell lymphoma | 2.4 | 7 | Citations (PDF) |
| 204 | Uterine carcinosarcoma metastatic to the lung as large-cell neuroendocrine carcinoma with synchronous sarcoid granulomatosis | 2.7 | 8 | Citations (PDF) |
| 205 | Early stage gastric diffuse large B-cell lymphomas: results of a randomised trial comparing chemotherapy alone<i>versus</i>chemotherapy + involved field radiotherapy | 1.5 | 29 | Citations (PDF) |
| 206 | Response to Neo-Adjuvant Chemotherapy for Colorectal Cancer Liver Metastases: A Key for Improving Survival? | 0.9 | 0 | Citations (PDF) |
| 207 | Subgroups of Diffuse Large B-Cell Lymphoma (DLBCL) with Different Genomic Lesions and Clinical Course During Treatment with R-CHOP.Blood, 2009, 114, 3957-3957 | 4.2 | 0 | Citations (PDF) |
| 208 | Rituximab and Chlorambucil as Front-Line Treatment in Untreated Follicular Lymphoma: a Combination with a Durable Response and Low Toxicity Profile.Blood, 2009, 114, 3754-3754 | 4.2 | 0 | Citations (PDF) |
| 209 | Dendritic cell sarcoma: An analytic overview of the literature and presentation of original five cases | 5.2 | 89 | Citations (PDF) |
| 210 | Extramedullary Myeloid Sarcoma of the Breast | 21.6 | 14 | Citations (PDF) |
| 211 | Efficacy of 90Y Ibritumomab-Tiuxetan Treatment in a Case of Resistant Gastric Malt Non Hodgkin's Lymphoma | 0.9 | 1 | Citations (PDF) |
| 212 | Primary diffuse large B-cell lymphoma of the breast: prognostic factors and outcomes of a study by the International Extranodal Lymphoma Study Group | 10.2 | 220 | Citations (PDF) |
| 213 | Lymph Node Metastases of Merkel Cell Carcinoma from Unknown Primary Site: Report of Three Cases | 1.5 | 22 | Citations (PDF) |
| 214 | The 70-gene prognosis-signature predicts disease outcome in breast cancer patients with 1–3 positive lymph nodes in an independent validation study | 2.4 | 273 | Citations (PDF) |
| 215 | Increasing steroid hormone receptors expression defines breast cancer subtypes non responsive to preoperative chemotherapy | 2.4 | 86 | Citations (PDF) |
| 216 | Array-CGH Identifies Regions, Including the FOXP1 Locus, Associated with Different Clinical Outcome in Diffuse Large B-Cell Lymphomas (DLBCL) Treated with R-CHOPBlood, 2008, 112, 478-478 | 4.2 | 0 | Citations (PDF) |
| 217 | Efficacy of 90 Y - Ibritumomab Tiuxetan in Relapsed or Refractory Primary Gastric Non Hodgkin LymphomaBlood, 2008, 112, 3063-3063 | 4.2 | 1 | Citations (PDF) |
| 218 | Evolving First-Line Treatments -from Chemotherapy to Immunotherapy Alone- in 143 Consecutive Follicular Lymphoma Patients Treated in the Last 14 Years at the European Institute of Oncology, MilanoBlood, 2008, 112, 5016-5016 | 4.2 | 5 | Citations (PDF) |
| 219 | Prognostic role of the extent of peritumoral vascular invasion in operable breast cancer | 10.2 | 100 | Citations (PDF) |
| 220 | Chlorambucil – rituximab as first line combination therapy in follicular non-Hodgkin's lymphoma: A clinical and biological analysis | 1.5 | 2 | Citations (PDF) |
| 221 | Chromosome instability and translocation t(11;18) in primary gastric marginal zone B‐cell lymphoma of MALT‐type | 2.2 | 8 | Citations (PDF) |
| 222 | Antitumour and biological effects of letrozole and GnRH analogue as primary therapy in premenopausal women with ER and PgR positive locally advanced operable breast cancer | 5.7 | 72 | Citations (PDF) |
| 223 | Pathologic complete remission rate after cisplatin-based primary chemotherapy in breast cancer: correlation with p63 expression | 2.2 | 20 | Citations (PDF) |
| 224 | Efficacy of 90Y-Ibritumomab Tiuxetan in Marginal-Zone Lymphoma (MZL).Blood, 2007, 110, 4499-4499 | 4.2 | 4 | Citations (PDF) |
| 225 | Continuous Immuno-Chemotherapy Followed by High Dose and Autologous Cell Transplantation May Improve the Event-Free-Survival in Mantle Cell Lymphoma Patients. Experience at the European Institute of Oncology in Milan.Blood, 2007, 110, 5116-5116 | 4.2 | 0 | Citations (PDF) |
| 226 | Combined VBM Chemotherapy and Involved Field (IF) Radiotherapy in Early Stage Hodgkin’s Lymphoma (HL): A Single Centre Experience.Blood, 2007, 110, 4463-4463 | 4.2 | 0 | Citations (PDF) |
| 227 | Report on a Case of Breast Sarcoma Metastatic to the Axillary Lymph Nodes | 1.5 | 3 | Citations (PDF) |
| 228 | Report on a Case of Pure Cribriform Carcinoma of the Breast with Internal Mammary Node Metastasis: Description of the Case and Review of the Literature | 1.5 | 8 | Citations (PDF) |
| 229 | Circulating endothelial-cell kinetics and viability predict survival in breast cancer patients receiving metronomic chemotherapyBlood, 2006, 108, 452-459 | 4.2 | 249 | Citations (PDF) |
| 230 | EFFECT OF RESECTION AND OUTCOME IN PATIENTS WITH RETROPERITONEAL SARCOMA | 0.8 | 9 | Citations (PDF) |
| 231 | Genomic and expression profiling identifies the B-cell associated tyrosine kinase Syk as a possible therapeutic target in mantle cell lymphoma | 2.4 | 174 | Citations (PDF) |
| 232 | Comparative genome-wide profiling of post-transplant lymphoproliferative disorders and diffuse large B-cell lymphomas | 2.4 | 59 | Citations (PDF) |
| 233 | Surgical outcomes after total mesorectal excision for rectal cancer | 1.6 | 40 | Citations (PDF) |
| 234 | Role of endocrine responsiveness and adjuvant therapy in very young women (below 35 years) with operable breast cancer and node negative disease | 10.2 | 75 | Citations (PDF) |
| 235 | SP4, a Novel Anti-Cyclin D1 Rabbit Monoclonal Antibody, Is a Highly Sensitive Probe for Identifying Mantle Cell Lymphomas Bearing the t(11;14)(q13;q32) Translocation | 1.0 | 14 | Citations (PDF) |
| 236 | Predicting the Risk for Additional Axillary Metastases in Patients With Breast Carcinoma and Positive Sentinel Lymph Node Biopsy | 4.7 | 229 | Citations (PDF) |
| 237 | Gene expression profiling of plasma cell dyscrasias reveals molecular patterns associated with distinct IGH translocations in multiple myeloma | 6.7 | 123 | Citations (PDF) |
| 238 | Immunoreactivity for c-kit and p63 as an adjunct in the diagnosis of adenoid cystic carcinoma of the breast | 4.9 | 98 | Citations (PDF) |
| 239 | Prognostic relevance of CD105+ microvessel density in HNSCC patient outcome | 2.5 | 76 | Citations (PDF) |
| 240 | Predicting the status of axillary sentinel lymph nodes in 4351 patients with invasive breast carcinoma treated in a single institution | 4.1 | 216 | Citations (PDF) |
| 241 | The transactivating isoforms of p63 are overexpressed in high-grade follicular lymphomas independent of the occurrence ofp63 gene amplification | 5.0 | 41 | Citations (PDF) |
| 242 | Clinical Activity of Rituximab in Gastric Marginal Zone Non-Hodgkin's Lymphoma Resistant to or Not Eligible for Anti–<i>Helicobacter Pylori</i> Therapy | 21.6 | 272 | Citations (PDF) |
| 243 | Unusual Cases in Multiple Myeloma and a Dramatic Response in Metastatic Lung Cancer | 21.6 | 5 | Citations (PDF) |
| 244 | Size of Breast Cancer Metastases in Axillary Lymph Nodes: Clinical Relevance of Minimal Lymph Node Involvement | 21.6 | 156 | Citations (PDF) |
| 245 | Endothelial precursors and mature endothelial cells are increased in the peripheral blood of myelodysplastic syndromes | 1.5 | 42 | Citations (PDF) |
| 246 | Association Between p53 Gene Mutations and Tobacco and Alcohol Exposure in Laryngeal Squamous Cell Carcinoma | 1.9 | 16 | Citations (PDF) |
| 247 | Impairment of p53 acetylation, stability and function by an oncogenic transcription factor | 7.4 | 112 | Citations (PDF) |
| 248 | Chronic idiopathic myelofibrosis: independent prognostic importance of bone marrow microvascular density evaluated by CD105 (endoglin) immunostaining | 4.9 | 20 | Citations (PDF) |
| 249 | Tailored therapy of adult acute leukaemia in Jehovah's Witnesses: unjustified reluctance to treat | 1.9 | 22 | Citations (PDF) |
| 250 | Cyclin D3 immunoreactivity in follicular lymphoma is independent of the t(6;14)(p21.1;q32.3) translocation orcyclin D3 gene amplification and is correlated with histologic grade and Ki-67 labeling index | 4.5 | 17 | Citations (PDF) |
| 251 | Histopathologic examination of axillary sentinel lymph nodes in breast carcinoma patients | 1.6 | 33 | Citations (PDF) |
| 252 | Prognostic Significance of P27 and Cyclin D1 Co-Expression in Laryngeal Squamous Cell Carcinoma: Possible Target for Novel Therapeutic Strategies | 1.7 | 7 | Citations (PDF) |
| 253 | Basaloid cell carcinoma of the prostate. Case report and review of the literature | 3.0 | 29 | Citations (PDF) |
| 254 | Prognostic value of bcl-6, CD10 and CD38 immunoreactivity in stage I-II gastric lymphomas: Identification of a subset of CD10+ large B-cell lymphomas with a favorable outcome | 4.5 | 29 | Citations (PDF) |
| 255 | Angiogenesis occurs in hairy cell leukaemia (HCL) and in NOD/SCID mice transplanted with the HCL line Bonna-12 | 2.4 | 18 | Citations (PDF) |
| 256 | Immunoreactivity for cyclin D3 is frequently detectable in high-grade primary gastric lymphomas in the absence of the t(6;14)(p21.1;q32.3) chromosomal translocation | 5.0 | 8 | Citations (PDF) |
| 257 | Cyclin D3 Immunoreactivity in Gastrointestinal Stromal Tumors Is Independent of Cyclin D3 Gene Amplification and Is Associated with Nuclear p27 Accumulation | 4.9 | 22 | Citations (PDF) |
| 258 | Intraepidermal cells of paget’s carcinoma of the breast can be genetically different from those of the underlying carcinoma | 2.4 | 57 | Citations (PDF) |
| 259 | Cell cycle regulators in multiple myeloma: Prognostic implications of p53 nuclear accumulation | 2.4 | 20 | Citations (PDF) |
| 260 | Idarubicin Containing Regimen in Multiple Myeloma: Preliminary Results of a Pilot Study Using a Modified "TANDEM" Transplant Program | 1.5 | 8 | Citations (PDF) |
| 261 | Ectopic Breast Tissue as a Possible Cause of False-Positive Axillary Sentinel Lymph Node Biopsies | 3.6 | 87 | Citations (PDF) |
| 262 | Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT typeBlood, 2003, 102, 2741-2745 | 4.2 | 410 | Citations (PDF) |
| 263 | Axillary Sentinel Lymph Node Biopsy in Patients With Pure Ductal Carcinoma In Situ of the Breast | 2.5 | 146 | Citations (PDF) |
| 264 | Sentinel Lymph Node Biopsy Performed With Local Anesthesia in Patients With Early-Stage Breast Carcinoma | 2.5 | 28 | Citations (PDF) |
| 265 | Lack of Bcl10 gene mutations in laryngeal squamous cell carcinoma | 0.9 | 1 | Citations (PDF) |
| 266 | In vitro and in vivo hematopoietic potential of human stem cells residing in muscle tissue | 0.4 | 34 | Citations (PDF) |
| 267 | Follicular dendritic cell sarcoma of the breast | 3.0 | 30 | Citations (PDF) |
| 268 | Microvessel density, a surrogate marker of angiogenesis, is significantly related to survival in multiple myeloma patients | 2.4 | 90 | Citations (PDF) |
| 269 | p63 immunoreactivity in lung cancer: yet another player in the development of squamous cell carcinomas? | 5.0 | 134 | Citations (PDF) |
| 270 | p63 in Laryngeal Squamous Cell Carcinoma: Evidence for a Role of TA-p63 Down-Regulation in Tumorigenesis and Lack of Prognostic Implications of p63 Immunoreactivity | 3.3 | 40 | Citations (PDF) |
| 271 | Monoclonal proliferation of germinal center cells (incipient follicular lymphoma) in an axillary lymph node of a melanoma patient | 2.4 | 21 | Citations (PDF) |
| 272 | Histologic detection and clinical implications of micrometastases in axillary sentinel lymph nodes for patients with breast carcinoma | 4.1 | 216 | Citations (PDF) |
| 273 | Clinical relevance of microvessel density in laryngeal squamous cell carcinomas | 4.5 | 27 | Citations (PDF) |
| 274 | Inhibition of angiogenesis and induction of endothelial and tumor cell apoptosis by green tea in animal models of human high-grade non-Hodgkin's lymphoma | 10.4 | 44 | Citations (PDF) |
| 275 | Endostatin induces tumor stabilization after chemo- or ANTI-CD20 therapy of high-grade non-hodgkin's lymphoma (Nhl) | 0.4 | 0 | Citations (PDF) |
| 276 | The thin red line | 0.4 | 77 | Citations (PDF) |
| 277 | Endostatin, an antiangiogenic drug, induces tumor stabilization after chemotherapy or anti-CD20 therapy in a NOD/SCID mouse model of human high-grade non-Hodgkin lymphoma | 4.2 | 86 | Citations (PDF) |
| 278 | Immunohistochemical Analysis of Cyclin D1 Shows Deregulated Expression in Multiple Myeloma with the t(11;14) | 3.4 | 75 | Citations (PDF) |
| 279 | Clinical Relevance of Expression of the CIP/KIP Cell-Cycle Inhibitors p21 and p27 in Laryngeal Cancer | 21.6 | 78 | Citations (PDF) |
| 280 | Angiogenesis in myelodysplastic syndromes | 5.7 | 261 | Citations (PDF) |
| 281 | Clinical relevance of p53 and bcl-2 protein over-expression in laryngeal squamous-cell carcinoma 1998, 79, 263-268 | | 46 | Citations (PDF) |
| 282 | Chromogranin A and B and secretogranin II in prostatic adenocarcinomas: Neuroendocrine expression in patients untreated and treated with androgen deprivation therapy 1998, 34, 113-120 | | 47 | Citations (PDF) |
| 283 | Low-grade MALT lymphoma involving multiple mucosal sites and bone marrow | 1.5 | 26 | Citations (PDF) |
| 284 | The predictive value of p53, MDM-2, cyclin D1 and Ki67 in the progression from low-grade dysplasia towards carcinoma of the larynx | 0.9 | 35 | Citations (PDF) |
| 285 | Cyclin D1 protein expression is related to clinical progression in laryngeal squamous cell carcinomas | 0.9 | 21 | Citations (PDF) |
| 286 | Polysialylated N-CAM, chromogranin A and B, and secretogranin II in neuroendocrine tumours of the lung | 3.0 | 17 | Citations (PDF) |
| 287 | Molecular and immunohistochemical analysis of thebcl-1/cyclin D1 gene in laryngeal squamous cell carcinomas 1997, 79, 1114-1121 | | 51 | Citations (PDF) |
| 288 | p53 and cyclin D1 protein expression in glottic laryngeal squamous cell carcinomas involving the anterior commissure (pT1bN0M0) | 4.0 | 1 | Citations (PDF) |
| 289 | Targeted RNA-sequencing analysis for fusion transcripts detection in tumor diagnostics: assessment of bioinformatic tools reliability in FFPE samples | 1.3 | 4 | Citations (PDF) |
